There is one clinical trial.
The prevention of obesity and its main medical complications, such as hypertension, type 2 diabetes and cardiovascular diseases, have been become a health priority. One of the most frequent metabolic complications in obesity is the insulin resistance and is the most important risk factor for the development of coronary diseases. The weight loss induced by the restriction of dietary energy is the cornerstone of therapy for people with obesity, as it improves or even regularizes insulin sensitivity and related comorbidities. However, weight loss induced by diet also decreases lean tissue mass, which could result in adverse effects on physical function. Although, regularly recommended to increase protein intake during weight loss, there is evidence to suggest that high protein intake could have deleterious metabolic effects. On the other hand, there is an association between the type of protein consumption, mainly the concentration of branched-chain amino acids (BCAAs) and insulin resistance during the dietary energy restriction in the therapy of obesity. There are multiple factors that influence the concentration of BCAAs and insulin resistance, which can be by phenotypic or genetic modification. The phenotypic modification refers to race, sex and dietary pattern. Meanwhile, the genetic modification refers to the activity of the enzymes responsible for the catabolism of BCAAs and genetic variants, such as the polymorphisms of a single nucleotide of said enzymes. A randomized controlled trial will be conducted with 160 participants (80 women and 80 men) divided by a draw in 4 groups, each for 20 participants. A feeding plan will be assigned according to the distribution of proteins (standard or high) and type of protein (animal or vegetable). The main aim of this study is to evaluate the effect on the amount and type of dietary protein and energy restriction on insulin resistance in subjects with obesity in a period of 1 month, considering the main factors that influence the concentration of BCAAs. In this way, evidence will be provided on what type of dietary intervention is most convenient for weight loss in subjects with insulin resistance and obesity.
Change of the HOMA index according to the presence or absence of polymorphism related to the metabolism of branched chain amino acids (rs11548193 and rs45500792).. HOMA (IR-HOMA) which is calculated glucose (mg / dl) x insulin (mUI / ml) / 405 before and after of dietary intervention.
Description: Change in the index HOMA-IR. The HOMA IR index will be calculated by the following equation: glucose (mg / dl) x insulin (mUI / ml) / 405 before and after of dietary intervention
Measure: Resistance insulin Time: Baseline to 1-monthDescription: Change in the concentration of the amino acid profile, mainly of branched chain amino acids
Measure: Amino acid profile Time: Baseline to 1-monthDescription: Change in fat mass, lean mass and skeletal muscle mass percentage
Measure: Change in body composition Time: Baseline to 1-monthDescription: change in body weight before and after of dietary intervention
Measure: Change in body weight Time: Baseline to 1-monthDescription: Change in waist circumference before and after of dietary intervention
Measure: Change in waist circumference Time: Baseline to 1-monthDescription: Change in grip strength before and after the intervention by dynamometry
Measure: Change in grip strength Time: Baseline to 1-monthDescription: The respiratory coefficient will be determined by indirect calorimetry
Measure: Change in respiratory quotient Time: Baseline to 1-monthDescription: The concentration of serum glucose will be determined by autoanalyzer before and after the intervention
Measure: Change in glucose serum Time: Baseline to 1-monthDescription: The concentration of serum total cholesterol will be determined by autoanalyzer before and after the intervention
Measure: Change in total cholesterol serum Time: Baseline to 1-monthDescription: The concentration of serum HDL-cholesterol will be determined by autoanalyzer before and after the intervention
Measure: Change in HDL cholesterol serum Time: Baseline to 1-monthDescription: The concentration of serum triglycerides will be determined by autoanalyzer before and after the intervention
Measure: Change in triglycerides serum Time: Baseline to 1-monthDescription: The concentration of serum LDL cholesterol will be determined by autoanalyzer before and after the intervention
Measure: Change in LDL cholesterol serum Time: Baseline to 1-monthDescription: The concentration of free fatty acids will be determined before and after the intervention
Measure: Change in free fatty acids serum Time: Baseline to 1-monthDescription: The concentration of serum liver enzymes will be determined by autoanalyzer before and after the intervention
Measure: Change liver function tests Time: Baseline to 1-monthDescription: The concentration of serum leptin will be determined by ELISA kit before and after the intervention
Measure: Change in concentration of leptin serum Time: Baseline to 1-monthDescription: The concentration of serum adiponectin will be determined by ELISA kit before and after the intervention
Measure: Change in concentration of adiponectin serum Time: Baseline to 1-monthDescription: The concentration of serum C- reactive protein will be determined by autoanalyzer before and after the intervention
Measure: Change in the concentration of C-reactive protein Time: Baseline to 1-monthDescription: the blod pressure will be determined before and after the intervention
Measure: Change in systolic and diastolic blood pressure Time: Baseline to 1-monthDescription: HOMA (IR-HOMA) which is calculated glucose (mg / dl) x insulin (mUI / ml) / 405 before and after of dietary intervention
Measure: Change of the HOMA index according to the presence or absence of polymorphism related to the metabolism of branched chain amino acids (rs11548193 and rs45500792). Time: Baseline to 1- month